Thank you for your interest in the B-Cell Directed Therapies for Autoimmune Diseases Summit.
2020 Registration is now closed. Make sure to join us next year!
Don't miss out on the 2021 launch date and Early Bird deadlines - register your interest now and we'll add you to our event mailing list.
Join key opinion leaders at a unique meeting dedicated to developing the next generation of B and plasma cell directed therapies with sustainable effectiveness in treating immune mediated disease and transformed patient outcomes
Several clinical trials of B and plasma cell directed therapies are demonstrating positive results across a broad range of non-oncological, immune mediated diseases including systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, multiple sclerosis, and Sjogren’s syndrome. However, the vast potential of developing next generation B cell directed therapies remains challenging with limited fundamental knowledge on the role of B and plasma cell subtypes in health, autoimmunity and the wider immune system.
Our virtual summit arrives as the first ever cross-disciplinary meeting for large pharma, biotech and academia. This forum is dedicated to harnessing the full therapeutic opportunity of numerous candidates directed against various B and plasma cell targets (incl. CD20, PI3K, BTK & more). Come armed with questions, ideas and experiences and together, take steps to develop the next generation of B cell directed therapies to improve immune mediated disease management, define effective combination treatment regimens and transform patient outcomes.
Join the B-Cell Directed Therapies for Autoimmune Diseases Summit to:
- Discover fundamental B and plasma cell biology to identify pathogenic subtypes and therapeutic targets with Duke University, Universities of Texas and Colorado
- Understand translational approaches and considerations for clinical trial design and patient stratification with Novartis and University of Rochester
- Examine the latest approaches targeting T & B cell crosstalk through T cell dependent mechanisms with AnTolRx, Akston Biosciences and Cour Pharmaceuticals
- Optimize small molecule inhibitor approaches that impact B cell function in autoimmunity with Incyte, Biogen and Principia Biopharma
- Explore next generation biologics approaches targeting pathogenic B cells with Jounce Therapeutics and Momenta Pharmaceuticals
World-Class Speaker Faculty
Senior Director - Pharmacology (Non- Oncology)
Principal Scientist: M267 CD38 SIFbody Program Co-Lead